Skip to main content
Equibles
CATX logo

CATX · Perspective Therapeutics, Inc. · Metrics

Track CATX — free

Use CATX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CATX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.81 +0.04 (+1.44%) At close · Sep 11
Russell 2000 member Rebalance outlook locked
Market Cap
$320.77M
Shares
114.15M

CATX metrics

64 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$2.81
Market cap
$320.77M

Price action

20 metrics
Price change (1W)
-11.2%
Price change (30D)
-10.6%
Price change (3M)
-6.7%
Price change (6M)
-45.8%
Price change (YTD)
+0.7%
Price change (1Y)
-14.2%
Trailing year
Price change (5Y)
—
52-week high
$5.65
52-week low
$2.05
Change from 52-week high
-51.0%
Change from 52-week low
+35.1%
Annualized volatility
109.3%
Annualized volatility (3M)
62.3%
Beta
1.0
RSI (14D)
34.6
Price vs SMA 50
-11.0%
Price vs SMA 200
-22.6%
Avg volume (3M)
1.59M
Relative volume
1.0
Average dollar volume
$4.94M

Company

3 metrics
Sector
Healthcare
Industry
Medical Devices
Shares outstanding
114.15M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
218.4×
reciprocal yield 0.5%
EV / EBITDA
—
EV / EBIT
—
P / sales
223.7×
reciprocal yield 0.4%
P / book
1.0
reciprocal yield 101.0%
FCF yield
-37.8%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-36.3%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
255.4×
reciprocal yield 0.4%
EV / revenue historical average (5Y)
255.4×
reciprocal yield 0.4%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2025-01-13

Profitability

9 metrics
Gross margin
100.0%
Operating margin
-2,855.0%
Trailing 12 months
Net margin
-3,243.2%
Gross profit (TTM)
$1.43M
Operating profit (TTM)
−$125.23M
Net income (TTM)
−$116.43M
Trailing 12 months
Diluted EPS (TTM)
$-1.33
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$2.78

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
$1.43M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+62.5%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-36.0%
Return on assets
-29.7%
Debt / equity
0.0
Current ratio
6.6
EBITDA (TTM)
−$121.18M
Free cash flow (TTM)
−$121.19M
Quick ratio
—
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$235.28M
Latest balance sheet
Cash & equivalents
$48.49M
Total assets
$392.02M
Total debt
$1.60M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$93.07M
Capital expenditures (TTM)
$28.12M
R&D (TTM)
$96.18M
SG&A (TTM)
—
Stock compensation (TTM)
$10.06M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
130
13F filer change QoQ
-9
Institutional ownership
76.5%

Short interest

3 metrics
Short interest
20.5%
Latest settlement · 23.6 days to cover
Days to cover
23.6d
Short-squeeze score
78 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$1.62M
Insider-sentiment score
20 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 728387 CUSIP 46489V302 13F (30d) 66 filings 66 filers Visit website Investor relations